by The global infertility drugs market consists of pharmaceutical agents used for fertility treatment. Some common infertility drugs include follicle-stimulating hormone (FSH), luteinizing hormone (LH), human menopausal gonadotropin (hMG), and clomiphene citrate. These fertility medications help increase the production of eggs and improve overall ovarian function in women. They can also help stimulate the production of testosterone and sperm in men.
The Global Infertility Drugs Market is estimated to be valued at US$ 4262.17 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Infertility Drugs are Koninklijke Philips N.V., LifeWatch USA, Tunstall, Apple Inc., ADT Security Services, Medical Guardian LLC, MobileHelp, Bay Alarm Company, MariCare Oy, Origin Wireless, The ADT Corporation, Singapore Technologies Electronics Limited, Semtech Corporation. The increasing rates of infertility due to changing lifestyles and rising stress levels is driving the growth of the infertility drugs market globally. According to WHO, around 48 million couples worldwide experience infertility. Developing regions including Asia Pacific and Latin America are witnessing higher growth in the infertility drugs market due to growing awareness and expanding healthcare infrastructure in these regions.
Market key trends
One of the key trends in the Global Infertility Drugs Market Size is the rising adoption of assisted reproductive technology (ART). ART includes procedures such as in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and pre-implantation genetic diagnosis (PGD). These advanced fertility treatments have revolutionized the way infertility issues are tackled. They have significantly higher success rates compared to oral fertility medication alone. This is expected to boost the demand for infertility drugs globally over the forecast period.
Porter’s Analysis
Threat of new entrants: High capital requirements and stringent regulations to enter IVF services and infertility treatment makes new entrants difficult.
Bargaining power of buyers: Buyers have moderate bargaining power given presence of several infertility clinicchains offering similar services. However, unique treatment needs keeps their power in check.
Bargaining power of suppliers: Suppliers of infertility drugs, devices and equipment enjoy low bargaining power due to availability of substitutes in the market.
Threat of new substitutes: Threat of new substitutes is moderate as infertility treatment requires continual innovation. Alternative fertility treatments like surrogacy or adoption are not always feasible substitutes.
Competitive rivalry: Intense competition exists between major players on factors like success rates, innovative treatments and geographic reach leading to high rivalry.
Geographical Regions
North America currently holds the largest share in the infertility drugs market owing to increasing infertility rates, rising healthcare expenditure and availability of advanced infertility treatment options in the region.
Asia Pacific region is expected to witness the highest growth during the forecast period due to growing medical tourism, rising disposable incomes, growing health awareness and expanding health infrastructure in emerging Asian countries.
North America currently holds the largest share in the infertility drugs market owing to increasing infertility rates, rising healthcare expenditure and availability of advanced infertility treatment options in the region.
Asia Pacific region is expected to witness the highest growth during the forecast period due to growing medical tourism, rising disposable incomes, growing health awareness and expanding health infrastructure in emerging Asian countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
